Results 271 to 280 of about 5,889,184 (390)
Advanced Science, EarlyView.LZU‐WZLYCS01 is a novel FGFR3‐targeting ADC for bladder cancer with 7‐ethyl‐9‐fluorocamptothecin (A2) as its cytotoxic payload. LZU‐WZLYCS01 intracellularly releases A2, which targets MAD2L1 to activate the cGAS‐STING pathway and induce tumor cell apoptosis.
Shu Cui +16 more
wiley +1 more source
Proteoglycans in Prostate Cancer Progression and Therapy Resistance. [PDF]
Medicina (Kaunas)Samaržija I.
europepmc +1 more source
Advanced Science, EarlyView.TMEM131 recruits the COPII complex to accelerate TRAIL transportation from endoplasmic reticulum to Golgi apparatus, and promotes soluble TRAIL secretion. TRAIL inhibits mitophagy and induces senescence through DR5 receptor in type II alveolar epithelial cells, ultimately driving radiation‐induced lung injury (RILI) progression.
Linzhi Han +10 more
wiley +1 more source
Results of 14 years of brachytherapy for localized prostate cancer in Denmark: the Herlev cohort
, 2018 Mikael G. Jacobsen +4 more
openalex +1 more source
Advanced Science, EarlyView.This study identifies the SOX9/TIMP1 axis as a key regulator of immune evasion in gastric cancer. iRGD‐conjugated nanoparticles co‐delivering si‐SOX9, Ce6, and L‐Arg are developed to synergize with photodynamic therapy. The nanoplatform suppresses tumor growth, promotes dendritic cell maturation, and enhances CD8+ T‐cell activation, offering a ...
Banghua Zhong +3 more
wiley +1 more source
TDP2 drives immune evasion and metastatic progression in prostate cancer. [PDF]
PLoS OneCao H, Pan A, Chen Y, Zheng F.
europepmc +1 more source